DOSE-RESPONSE RELATIONSHIPS FOLLOWING ORAL-ADMINISTRATION OF DUP 753 TO NORMAL HUMANS

被引：58

作者：

CHRISTEN, Y ^{[1
]}

WAEBER, B ^{[1
]}

NUSSBERGER, J ^{[1
]}

LEE, RJ ^{[1
]}

TIMMERMANS, PBMWM ^{[1
]}

BRUNNER, HR ^{[1
]}

机构：

[1] CHU VAUDOIS,DIV HYPERTENS,CH-1011 LAUSANNE,SWITZERLAND

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 04期

关键词：

ANGIOTENSIN-II; DUP; 753; ANGIOTENSIN-II ANTAGONIST;

D O I：

10.1093/ajh/4.4.350S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy volunteers. In a single dose study, doses of 2.5, 5, 10, 20, and 40 mg of DuP 753 or placebo were tested serially at one week intervals. In the multiple dose study, the administration of placebo or DuP 753 (5, 10, 20, or 40 mg, per os once daily) for eight consecutive days was evaluated. The blood pressure response to angiotensin I and II was inhibited in a dose-dependent fashion with a blocking effect still present 24 h post drug. DuP 753 also induced a dose-dependent compensatory rise in plasma renin. This new compound was well tolerated by these normal volunteers. Thus, DuP 753 appears to be a well tolerated, orally active, potent and long-lasting antagonist of angiotensin II in humans.

引用

页码：S350 / S353

页数：4

共 19 条

[1]

Pals D.T., Masucci F.D., Sipos F., Denning C.S., A specific competitive antagonist of the vascular action of angiotensin II, Circ Res, 29, pp. 664-672, (1971)

[2]

Brunner H.R., Gavras H., Laragh J.H., Keenan R., Angiotensin II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure, Lancet, 2, pp. 1045-1048, (1973)

[3]

Brunner H.R., Gavras H., Laragh J.H., Keenan R., Hypertension in man, exposure of the renin and sodium components using angiotensin II blockade, Circ Res, 34, 1, pp. 35-43, (1974)

[4]

Streeten D., Erson G.H., Fruiberg J.M., Dalakos T.G., Use of an angiotensin II antagonist (Saralasin) in the recognition of angiotensinogenic hypertension, N Engl J Med, 292, pp. 657-662, (1975)

[5]

Furukawa Y., Kishimoto S., Nishikawa K., Hypotensive Imidazole Derivatives. US Patent 4, 340, 598 Issued to Ta-Keda Chemical Industries, Ltd., (1982)

[6]

Timmermans P., Carini D.J., Chiu A.T., Et al., Angiotensin II receptor antagonists, Am J Hypertens, 3, pp. 599-604, (1990)

[7]

Wong P.C., Price W.A., Chiu A.T., Et al., Nonpeptide angiotensin II receptor antagonists: VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent, J Pharmacol Exp Ther, 252, pp. 719-725, (1990)

[8]

Wong P.C., Price W.A., Chiu A.T., Et al., Hypotensive action of DuP 753, an angiotensin II antagonist in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X, Hypertension, 15, pp. 459-468, (1990)

[9]

Wong P.C., Price W.A., Chiu A.T., Et al., Nonpeptide angiotensin II receptor antagonists: Studies with EXP 9270 and DuP 753, Hypertension, 15, pp. 823-834, (1990)

[10]

Christen Y., Nussberger J., Waeber B., Et al: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers

← 1 2 →